Table 2.
Univariate and multivariate analyses for survival
| Independent factor | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | |
| Sex | 0.7321 | |||||
| Female | 1.000 | reference | ||||
| Male | 1.066 | 0.742–1.557 | ||||
| Age (years) | 0.2095 | |||||
| < 70 | 1.000 | reference | ||||
| ≥ 70 | 1.257 | 0.878–1.786 | ||||
| Therapeutic type | 0.0227 | 0.1226 | ||||
| Chemoradiotherapy | 1.000 | reference | 1.000 | reference | ||
| Chemotherapy | 5.369 | 1.199–94.547 | 3.499 | 0.770–61.865 | ||
| Tumor response | < 0.0001 | < 0.0001 | ||||
| Non-PD | 1.000 | reference | 1.000 | reference | ||
| PD | 5.145 | 3.523–7.522 | 4.226 | 2.834–6.328 | ||
| NLR-PLR score | < 0.0001 | 0.0392 | ||||
| 0 | 1.000 | reference | 1.000 | reference | ||
| 1 | 1.923 | 1.259–2.991 | 0.0023 | 1.363 | 0.875–2.157 | 0.1726 |
| 2 | 3.296 | 2.027–5.390 | < 0.0001 | 1.958 | 1.167–3.299 | 0.0110 |
CI confidence interval, NLR neutrophil–lymphocyte ratio, PD progressive disease, PLR platelet–lymphocyte ratio